Antiviral Protection and Germinal Center Formation, But Impaired B Cell Memory in the Absence of CD19

By Thomas Fehr,* Robert C. Rickert,‡ Bernhard Odermatt,* Jürgen Roes,‡ Klaus Rajewsky,‡ Hans Hengartner,* and Rolf M. Zinkernagel*

From the *Institute of Experimental Immunology, Department of Pathology, University Hospital, CH-8091 Zürich, Switzerland; and the ‡Institute for Genetics, University of Cologne, D-50931 Cologne, Germany

Summary

Coligation of CD19, a molecule expressed during all stages of B cell development except plasmacytes, lowers the threshold for B cell activation with anti-IgM by a factor of 100. The cytoplasmic tail of CD19 contains nine tyrosine residues as possible phosphorylation sites and is postulated to function as the signal transducing element for complement receptor (CR)2. Generation and analysis of CD19 gene–targeted mice revealed that T cell–dependent (TD) antibody responses to proteinaceous antigens were impaired, whereas those to T cell–independent (TI) type 2 antigens were normal or even augmented. These results are compatible with earlier complement depletion studies and the postulated function of CD19. To analyze the role of CD19 in antiviral antibody responses, we immunized CD19−/− mice with viral antigens of TI-1, TI-2, and TD type. The effect of CD19 on TI responses was more dependent on antigen dose and replicative capacity than on antigen type. CR blocking experiments confirmed the role of CD19 as B cell signal transducer for complement. In contrast to immunization with protein antigens, infection of CD19−/− mice with replicating virus led to generation of specific germinal centers, which persisted for >100 d, whereas maintenance of memory antibody titers as well as circulating memory B cells was fully dependent on CD19. Thus, our study confirms a costimulatory role of CD19 on B cells under limiting antigen conditions and indicates an important role for B cell memory.

Key words: CD19 • antiviral immunity • complement • germinal center • B cell memory

CD19 is a 95-kD transmembrane protein of the Ig superfamily. It is specifically expressed on B cells, from early progenitors in the bone marrow to memory cells, except for antibody-forming plasma cells (1). Therefore, it is used as a major target for immunotherapy approaches to B cell leukemias (2). CD19 exhibits a highly conserved structure of two extracellular Ig domains and a 243-amino acid long cytoplasmic tail with nine tyrosine residues as possible phosphorylation sites (3, 4). These structural features contribute to its known signaling ability. Upon cross-linking, CD19 associates with the protein tyrosine kinases lyn (5) and fyn (6), and signaling via vav/ras/mitogen-activated protein kinase and the phosphatidylinositol 3-kinase pathways are initiated (7). Phospholipase Cγ is also activated (8), leading to the generation of inositol triphosphate (9) and to Ca2+ mobilization (10).

On mature B cells, CD19 associates in vitro and in vivo with three different molecules to form a tetrameric complex: CR2 (CD21), target of the antiproliferative antibody 1 (CD81), and Leu-13 (11, 12). These associations have led to the concept that CD19 is the signal transducer for CR2, which may not possess intrinsic signaling properties since it has a short cytoplasmic domain. In addition, CD19 can associate directly with the B cell receptor (13, 14). CD19 is necessary for formation of the peritoneal B-1 cell population (15–18). Treatment of pregnant mice with an anti-CD19 antibody led to the loss of B-1 cells in the offspring (16). This finding correlates with a severe and selective B-1 cell deficiency in CD19−/− mice (17, 18). In mature B lymphocytes, CD19 mediates homotypic aggregation (19) and functions as a B cell costimulator, since coligation of CD19 lowers the threshold for B cell activation with anti-IgM antibody by a factor of 100 (20). Complement, especially its activated component C3d, is
known to exert B cell costimulatory activity in antibody responses to T cell–dependent (TD)\(^1\) antigens (21) and in general, under limiting antigen doses (22, 23). This was shown first by complement depletion experiments with cobra venom factor (CVF [24]), later by treatment of mice with anti-complement receptor (CR) antibodies (25, 26) or soluble CD21 (27), and most recently by the generation of C3- and CR2-deficient mice (28–30). We demonstrated recently that neutralizing IgM antibodies to vesicular stomatitis virus (VSV) were mostly complement-independent except when limiting antigen doses were used. In contrast, the TD switch to IgG was dependent on complement (31). Binding of C3 to antigen, which has been demonstrated for VSV (32), may allow coligation of surface (sIg and CR (“dual antigen recognition” [33]). The recent observation that immunization with a recombinant hen egg lysozyme (‘dual antigen recognition’ [33]) may allow coligation of surface (sIg and CR 2-deficient mice (28–30). We demonstrated or soluble CD21 (27), and most recently by the generation with anti-complement receptor (CR) antibodies (25, 26) bra venom factor (CVF [24]), later by treatment of mice general, under limiting antigen doses (22, 23). This was 

1\(^*\)Abbreviations used in this paper: AFC, antibody-forming cell; Bac VSV-G, baculovirus-derived VSV-G; BSS, balanced salt solution; CVF, cobra venom factor; FDC, follicular dendritic cell; GC, germinal center; LCMV, lymphocytic choriomeningitis virus; LCMV-NP, LCMV nucleoprotein; PNA, peanut agglutinin; RT, room temperature; sIg, surface Ig; TD, T cell–dependent; T1, T cell–independent; vacc VSV-G, recombinant vaccinia virus expressing VSV-G; VSV, vesicular stomatitis virus VSV-G, VSV glycoprotein; VSV-IN D, VSV Indiana serotype.

\(^2\)Mic: CD19\(^{-/-}\), C57BL/10ScN, and C57BL/6 mice were obtained from the breeding colony of the Institut für Labor- tierkunde, Veterinary Hospital (Zurich, Switzerland). Breedinges were performed under specific pathogen–free conditions, whereas experiments were done in conventional animal facilities. Mice were used at 8–12 wk of age.

\(^{\text{Virus}}\) VSV serotype Indiana (VSV-IN D; Mudd-Summers isolate) was obtained originally from Prof. D. Kolakowsky, University of Geneva (Geneva, Switzerland). It was grown on BHK cells in MEM supplemented with 5% FCS at 37°C. LCMV (isolate WE) had been obtained originally from Dr. F. Lehmann-Grube, Heinrich Pette Institut für Experimentelle Virologie und Immunologie, University of Hamburg (Hamburg, Germany). The recombinant baculoviruses expressing the glycoprotein of VSV (VSV-G) and the nucleoprotein of LCMV (LCMV-NP) were a gift from Dr. D.H.L. Bishop, NERC Institute of Virology (Oxford, UK). They were derived from nuclear polyhedrosis virus and were grown at 28°C in Spodoptera frugiperda cells in spinner cultures in TC-100 medium (41).

CVF and Anti-CR Antibody. Purified CVF (Naja naja) was obtained from Sigma Chemie (33350; Buchs, Switzerland). We injected twice 1.2 \(\mu\)g of CVF diluted in 200 \(\mu\)l of balanced salt solution (BSS) with an interval of 8–10 h, 16 h before immunization. The anti-CR antibody 7G6 was a gift of Prof. T. Kinoshita, Department of Immunoregulation, Research Institute for Microbial Diseases, Osaka University (Osaka, Japan). It cross-reacts extensively on CR2 and CR1 and induces a downregulation of these receptors for ~7 d. 200 \(\mu\)g of antibody was diluted in 200 \(\mu\)l of BSS and injected once intravenously 1 d before immunization (25).

Immunizations. For immunizations with live virus or baculovirus-derived VSV-G (Bac VSV-G), \(2 \times 10^8\) PFU of VSV or 10 \(\mu\)l of Bac VSV-G, respectively, were injected in 200 \(\mu\)l of BSS i.v. or i.p. Alternatively, the same amount of virus or protein was mixed 1:1 with IFA and then injected subcutaneously at the base of tail.

Formalin inactivation of VSV-IN D was performed by addition of 16 \(\mu\)l of 4% formalin to 1 ml of VSV-IN D at a concentration of 10^6 PFU/ml (final formalin concentration 0.0625% [42]). The mixture was incubated at 4°C for 16 h. Before infection, inactivated virus was diluted with BSS so that 200 \(\mu\)l could be injected intravenously in every experiment. VSV Neutralization Assay. Neutralizing titers of sera were determined as described (43). In brief, the sera were prediluted 40-fold in MEM supplemented with 5% FCS, then heat inactivated for 30 min at 56°C. Serial twofold dilutions were mixed with equal volumes of VSV diluted to contain 500 PFU/ml. The mixture was incubated for 90 min at 37°C in an atmosphere with 5% CO\(_2\). 100 \(\mu\)l of serum–virus mixture was transferred onto Vero cell monolayers in 96-well plates and incubated for 1 h at 37°C. An overlay of 100 \(\mu\)l DMEM containing 1% methylcellulose was added. After incubation for 24 h at 37°C, the overlay was flicked off, and the monolayer was fixed and stained with 0.5% crystal violet. The highest dilution of serum that reduced the amount of plaques by 50% was taken as the neutralizing titer. Titers are indicated as –log\(_2\) of 40-fold prediluted sera. To determine IgG titers, undiluted serum was first pretreated with an equal volume of 0.1 M 2-mercaptoethanol in saline (44).

LCMV-NP–specific ELISA. We used a sandwich ELISA with the following steps: (a) coating with baculovirus-derived LCMV-NP (1 \(\mu\)g/ml); (b) blocking with 2% BSA (Fluka AG, Buchs, Switzerland) in PBS; (c) 20-fold prediluted mouse serum, titrated 1:2 over 10 dilution steps (d) IgM- or IgG-specific horseradish peroxidase–labeled goat anti–mouse antibodies (0.5 \(\mu\)g/ml; Southern Biotechnology Associates, Inc., Birmingham, AL); and (e) substrate ABTS (2,2′-azino-bis[3-ethylbenzthiazoline-6-sulfonate]); Boehr-
ringer Mannheim, Germany) and H$_2$O$_2$ (Fluka AG). Plates were coated overnight at 4°C; all other incubations were for 60–90 min at room temperature (RT). Between incubations, plates were washed three times with PBS containing 0.5 ml Tween 20 per liter. OD was measured at 405 nm in an ELISA reader.

Enzyme-linked Immunospot Assay for VSV-specific Antibody-forming Cells. Antibody-forming cell (AFC) frequencies were determined as described (45, 46). In brief, 25-square well polystyrene plates were coated with purified VSV (~5 × 10$^8$ PFU/ml). On the next day, plates were blocked with 2% BSA in PBS (see ELISA, above) for 2 h. Titrated amounts of spleen or bone marrow cells (titration 1:5 over four dilution steps starting with 5 × 10$^6$ cells/well) were added in 2% MEM and incubated for 5 h at 37°C. After washing with PBS-Tween (see ELISA, above), goat anti–mouse IgG antibody (2 μg/ml; E·Y Labs, San Mateo, CA) was added, and plates were incubated for 2 h at 37°C. After washing with PBS-Tween, alkaline phosphatase–labeled donkey anti–goat antibody (1 μg/ml; Jackson ImmunoResearch Labs, West Grove, PA) was added, and plates were incubated overnight at RT. On the next day, plates were washed, and the substrate solution (5-bromo-4-chloro-3-indolyl phosphate at 1 mg/ml in 0.6% agarose) was added to develop blue color spots. AFC numbers were then calculated per 10$^6$ nucleated cells.

Adoptive Transfer Experiments. Single cell suspensions of splenocytes from VSV-IND–primed normal or CD19$^{−/−}$ mice were injected intravenously into irradiated (450 rad) recipients. Donor cells were pooled from two individuals, and 10$^7$ spleen cells were transferred to each host (groups of three animals). Recipient mice were then challenged 24 h after transfer with 2 × 10$^5$ PFU of formalin-inactivated VSV. Blood was taken on day 3 after challenge to determine neutralizing IgG titers.

Immunohistochemistry. Freshly removed organs were immersed in HBSS and snap frozen in liquid nitrogen. Tissue sections of 5-μm thickness were cut in a cryostat, placed on siliconized glass slides, air dried, fixed with acetone for 10 min, and stored at −70°C. Secondary affinity-purified polyclonal anti-Ig antisera were diluted in Tris-buffered saline (TBS, pH 7.4) containing 5% mouse serum. All other dilutions were made in TBS alone. Incubations were done at RT for 30 min; TBS was used for all washing steps. Alkaline phosphatase was visualized using naphthol AS-BI (6-bromo-2-hydroxy-3-naphtholic acid-2-methoxy anilide) phosphate and new fuchsin as substrate. Endogenous alkaline phosphatase was blocked by levamisole. All color reactions were performed at RT for 15 min with reagents from Sigma Chemical Co. (St. Louis, MO). Sections were counterstained with hemalum. Coverslips were mounted with glycerol and gelatin.

Staining for VSV-specific B cells was done as described (47). For staining of cell differentiation markers, rehydrated tissue sections were incubated with the rat primary mAbs anti-FDC (4C11 [48]) and anti-B220 (RA3-6B2; PharMingen, San Diego, CA). Primary rat mAbs were revealed by a twofold sequential incubation with rabbit anti–rat Ig and rat alkaline phosphatase anti–alkaline phosphatase complex (Dakopatts A/S, Glostrup, Denmark). GCs were stained with peanut agglutinin (PNA [47]).

**Figure 1.** Antibody responses to replicating and nonreplicating viral antigens of TI-1, TI-2, and TD type. (A–D) Mice were immunized intravenously with either 2 × 10$^5$ PFU of live (A) or formalin-inactivated VSV (B), vacc VSV-G (C), or 10 μg of Bac VSV-G, and sera for determination of VSV-neutralizing titers were taken at the indicated time points. Each data point represents the mean of two to three mice. (E and F) Mice were immunized with 200 PFU of live LCMV intravenously (E) or 300 μl of purified LCMV in CFA subcutaneously (F), and sera were taken on day 16 after immunization to test for LCMV-NP–binding antibodies in ELISA. Each line indicates an individual mouse. All experiments were done with two to three mice per group and repeated at least once. Filled symbols, CD19$^{−/−}$; open symbols, CD19$^{+/−}$; squares, IgM; circles, IgG.
**Results**

Normal Antibody Titers against Replicating, But Reduced Titers against Nonreplicating TI-1 or TI-2 VSV-G Antigens. Primary neutralizing antibody responses to four different forms of VSV-G were tested (Fig. 1, A–D). VSV-G exposed in a highly repetitive order on live or formalin-inactivated viral particles has been shown to induce neutralizing IgM responses completely independent of T cells, i.e., as a TI-1 antigen. In contrast, VSV-G on the membrane of cells infected with a recombinant vaccinia virus expressing VSV-G (vacc VSV-G) and Bac VSV-G are TI-2 antigens (49). For all types of VSV-G antigens, the IgG response is TD (50).

CD19−/− mice immunized with 2 × 10⁶ PFU of live VSV (Fig. 1 A) or vacc VSV-G (Fig. 1 C) exhibited normal neutralizing VSV-G-specific antibody titers, although in the latter case, induction of IgM antibodies was delayed 3 d compared with control mice. CD19−/− mice survived these infections normally without displaying any morbidity. In contrast, antibodies to formalin-inactivated VSV (Fig. 1 B) and Bac VSV-G protein (Fig. 1 D) were reduced markedly. This result differs from recent experiments with haptenated antigens, where the TI-2 response to DNP-Ficoll (36) but not to NP-Ficoll (17) was enhanced.

TD Anti-LCMV Antibodies Are CD19-dependent for Replicating and Nonreplicating Antigens. Antibodies to LCMV have been shown to be dependent on T helper cells for the IgM and IgG response. Therefore, we tested CD19−/− mice for their capacity to mount LCMV-NP-specific antibodies after immunization with either live virus intravenously (100 PFU LCMV strain WE; Fig. 1 E) or with UV-inactivated virus subcutaneously (300 µl of purified LCMV in CFA corresponding to ~20 µg of protein; Fig. 1 F). IgG (Fig. 1, E and F) as well as IgM (data not shown) to both types of antigens were decreased when measured in an NP-specific ELISA. This result confirms the published severe defect of these mice in TD antibody responses (17, 18). But there is a striking difference between a low dose of replicating and a high dose of inactivated virus in CD19−/− mice; only the latter nonreplicating antigen failed to induce IgG antibodies in CD19−/− mice.

**Table 1. Dependence of VSV Neutralizing Antibodies on Application Route**

| Mouse strain: | CD19+/+ | CD19−/− |
|--------------|---------|---------|
| Neutralizing antibody: | IgM, day 4 | IgG, day 12 | IgM, day 4 | IgG, day 12 |
| VSV live | | | |
| i.v. | 9/8/8* | 12/12/11 | 9/9/8 | 12/10/9 |
| s.c. | 8/7/7 | 12/10/9 | 9/7/4 | 12/11/8 |
| i.p. | 9/8 | 13/13 | 7/6/5 | 10/9/7 |
| VSV form | | | |
| i.v. | 10/9 | 13/12 | 7/6/5 | 10/9/7 |
| i.p. | 7/7/6 | 4/2/1 | 0/0/0 (day 4) | 0/0/0 |
| 3/1/1 (day 12) |
| Bac VSV-G | | | |
| i.v. | 8/8/7 | 9/9/7 | 6/5/5 | 4/3/2 |
| s.c. | 6/5 | 5/4 | 4/1 | 1/1 |
| i.p. | 8/8/8 | 9/9/8 | 7/7/7 | 8/7/6 |

*Neutralizing titers are indicated as −log₂ of 40-fold prediluted sera. Each number indicates the titer of an individual mouse. Each experiment was repeated once or twice.

The Route of Antigen Administration Selectively Influences Antiviral Antibody Responses in CD19−/− Mice. B cell development in CD19−/− mice has been shown to be virtually normal except for a severe reduction of peritoneal B-1 cells (17, 18). To see whether this has any consequence for antiviral antibodies, we immunized CD19−/− and control mice with live VSV, formalin-inactivated VSV, or Bac VSV-G via three different application routes (Table 1): intravenously, subcutaneously in IFA, or intraperitoneally. In the case of Bac VSV-G, the reduction in neutralizing titers in CD19−/− mice was comparable for all three application routes, although it was slightly more pronounced after subcutaneous immunization; this indicated that IFA could not compensate for a CD19-mediated costimulation of B cells.

In contrast, after intraperitoneal immunization with live or, with a much more pronounced effect, formalin-inactivated virus, neutralizing titers were reduced by a factor of 8–100, suggesting a role for B-1 cells in early anti-VSV immune responses after intraperitoneal infection.

Interactions between CD19 and the Complement System. To test the hypothesis that CD19 functions as a signal transducer for CR2, we looked for the ability of CD19−/− mice to produce VSV-specific neutralizing antibodies after interference with the complement system in two different
ways, either the complement component C3 was depleted by CVF (Fig. 2A), or the complement receptors CR1 and CR2 were blocked by the mAb 7G6 (Fig. 2B). Mice were then immunized with 2 x 10^6 PFU of formalin-inactivated VSV.

Both treatments led to more pronounced reduction of IgG than IgM responses, confirming earlier results showing that VSV activates B cells to produce IgM mostly independently of additional signals, whereas switch to IgG depends on CD4+ T cells and complement (31). In addition, Fig. 2 shows that (a) the titers in CD19^-/- mice were lower than in C3-depleted or (less pronounced) in anti-CR-treated controls, and (b) C3 depletion led to a further reduction in CD19^-/- mice. This second finding suggests that complement has effects on B cells that are not CD19 mediated, as for example an opsonizing function of complement for enhanced antigen presentation (51). The first finding could be explained by incomplete blocking of the complement system with CVF or anti-CR, or it may indicate a direct complement-independent function of CD19 on B cells. Whether this needs triggering via a separate potential CD19 ligand is not known. But direct association of CD19 with sIgM on B cells has already been demonstrated (13, 14), and may indicate a direct influence on sIg signaling by CD19 (52).

CD19 is crucial for antiviral B cell memory. More than 20 years ago, an important role of complement for maintenance of B cell memory was postulated (53) and later confirmed (54, 55). By opsonization of antigen or immune complexes, complement would either enhance the persistence of antigen on follicular dendritic cells (FDCs) or deliver special signals to memory cells via CRs. Since CR2 is thought to transduce signals through CD19 during T cell recognition, we looked at B cell memory in CD19^-/- and control animals. These mice were immunized with a standard dose of 2 x 10^6 PFU of VSV, which is known to induce life-long immunity in mice (47). To assess B cell memory, we chose three different readouts. (a) First, we looked at maintenance of neutralizing IgG titers over ~100 d after immunization with live VSV (Fig. 3A) or Bac VSV-G (Fig. 3D). After live VSV infection of CD19^-/- mice, neutralizing antibody titers dropped from 10 to 2 within 105 d, and after immunization with Bac VSV-G, they dropped to 1 within 30 and 0 within 120 d. In both experiments, control animals maintained the titers obtained by day 20 within a factor of two to four (or within one to two titer steps). (b) As a readout for memory B cells, we took spleen cells from animals of the same experiment as in Fig. 3A at three different time points and adoptively transferred them into irradiated recipient mice. 1 d after transfer, the recipients were challenged with 2 x 10^6 PFU of formalin-inactivated virus, and neutralizing IgG titers of 3 d after challenge were taken as a readout of B cell memory (Fig. 3B). In control mice, the memory titers after challenge did not drop significantly over 105 d, whereas in CD19^-/- mice, a significantly lower titer than in controls could be measured as early as day 12. This titer had disappeared completely by the later time points tested. In a similar experiment (Fig. 3E), memory spleen cells were transferred into irradiated transgenic recipients expressing the VSV-G either as a soluble protein in the serum (Monitor [56]) or under a class I promoter on the membrane of most cells (KINDG [57]). The antigenicity of these transgenes has been shown previously to restimulate memory B cells (58). Although in Monitor mice, only CD19-competent cells were able to mount a small neutralizing titer, in KINDG mice, CD19^-/- cells also produced some neutralizing antibody, but at least 100-fold lower than control cells. (c) As a readout for VSV-specific AFCs (Fig. 3E), enzyme-linked immunospot assays of bone marrow and spleen cells were performed, again from animals of the experiment described in Fig. 3A. Plasma cell frequencies were determined at three different time points. Although neutralizing antibody titers in the serum did not differ between CD19^-/- and control mice 12 d after immunization, AFC frequencies in CD19^-/- mice were already lower by a factor of eight in the spleen and almost undetectable in the bone marrow. After 46 and 105 d, AFC numbers in CD19^-/- mice were below the detection level, whereas in CD19-competent mice, significant numbers of plasma cells could be measured in spleen and bone marrow for up to 105 d.

CD19 is not necessary for the generation of VSV-specific GCs. A severe defect in the generation of GCs after immunization with TD antigens has been described for CD19^-/- (17, 36) as well as C3^-/- (59) and CR^-/- mice (60). Since maintenance of B cell memory is thought to be governed by persisting antigen in immune complexes on FDCs in GCs (61), we wanted to see whether the loss of VSV-specific B cell memory in CD19^-/- mice was due to the failure to generate GCs. From the same mice shown in Fig. 3A, spleen sections were prepared and stained immunohistochemically for VSV-specific B cells (see M&L and Methods), and reference 47; Fig. 4, A and B), GCs (PNA; Fig. 4, C and D), FDCs (4C11; Fig. 4, E and F).
and total B cells (B220; Fig. 4, G and H). Fig. 4 shows spleen sections derived from the group of mice killed 46 d after immunization. Surprisingly, in CD19−/− as well as in CD19-competent mice, VSV-specific GCs could be observed until day 105; despite this, the former mice lost their neutralizing antibody titers. Quantitative analysis (Table 2) showed a difference in numbers of GCs, with the CD19−/− mice about twofold lower than the controls. In addition, GCs of CD19−/− mice appeared smaller in size (diameter reduction of ~30%). Quantitative analysis of overall GC numbers yields a reduction of maximally sevenfold [(1.5)^3 × 2 = 6.75]. This reduction is substantial, but cannot explain the total loss of VSV-specific neutralizing antibodies solely on a quantitative basis. In general, CD19 was apparently not necessary for generation of antigen-specific GCs to VSV-G-neutralizing epitopes.

**Discussion**

The role of CD19 and associated CR2 for costimulation of B cells has been clearly demonstrated in vitro as well as with CD19−/− (17, 18) and CR−/− mice (29, 30) in vivo. Complement has been postulated to have a bridging role between innate and adaptive immunity (35). This study first looked at B cell responses to live virus infections in CD19−/− mice. Mice were immunized with VSV, which induces TI-1 IgM antibody response and is controlled by the subsequent TD IgG response; alternatively, vacc VSV-G was used, which induces TI-2 antibodies and is controlled by cytokines and T cells, or LCMV, an Arenavirus that induces strictly TD antibody responses and is controlled by cytotoxic T cells. CD19−/− mice were protected against all of these infections and did not show any morbidity. Consistent with published results from studies with haptenated protein antigens, the TD antibody responses were reduced markedly. But in contrast to another study (15), TI-2 responses were not enhanced, and TI-1 responses were only reduced when nonreplicating antigen was used. This finding may be explained by the following: (a) immunization with live virus, even if only an abortive replication cycle occurs, may produce a greater antigen load. This correlates with published studies that show decreasing dependence of B cells upon costimulation via complement and probably CD19 with increasing antigen dose (22, 23, 31). (b) In contrast to protein antigens, immunization with live virus always leads to nonspecific inflammatory reactions and secretion of cytokines (62), among which IFN-α has been shown to bind to CR2 (63) and to provide survival signals for GC B cells (64). Whether this mechanism has any relevance during infections needs to be further investigated. Our results at least indicate that such a stimulation via CR2 would be independent of CD19.
Figure 4. Immunohistochemical staining of memory spleen sections after VSV infection. Spleen sections of the same mice as in Fig. 3, A–C (time point day 46), were analyzed by immunohistochemistry and stained for VSV-specific B cells (A and B), GC B cells (PNA; C and D), FDCs (4C11; E and F), and B cells in general (B220; G and H). Original magnifications are ~80-fold.
CD19\(^{-/-}\) animals have a severe defect in the formation of B-1 B cells, whereas B-2 cells are normal or only slightly reduced. B-1 cells are thought to produce natural antibodies that may also be involved in autoimmunity (65) as well as in early defense mechanisms against pathogens. Whether the absence of CD19 and the defect in peritoneal B-1 cells have consequences for antiviral immunity was investigated here by comparing immunizations with VSV via various infection routes. Indeed, when the virus was given intraperitoneally, neutralizing antibody titers were reduced. This difference was even more drastic when the virus was inactivated. But in the case of live virus infection, it did not have any effect on protection of CD19\(^{-/-}\) animals. These results may indicate a crucial role of the route of antigen application, or they reveal a biological function of the B-1 cell compartment.

GC formation in CD19\(^{-/-}\) mice has been shown to be severely impaired after immunization with haptenated protein antigens (17, 36). But consequences for generation of B cell memory have not been analyzed. These results indicate that memory antibody titers, AFC frequencies, and memory B cells detected by adoptive transfer are severely impaired in these mice. Most probably, the generation of memory B cells is already affected, because—although antibody titers 12 d after infection were comparable to control mice—AFC and memory B cells were already clearly reduced at that time. This finding was independent of the generation of GCs, which could be found in both CD19\(^{-/-}\) and control animals, even at >100 d after infection, as described for the latter (47). These findings question the strict correlation between GC formation and establishment or possibly maintenance of B cell memory (66). GCs are thought to be the structural environment where somatic mutation occurs, high-affinity B cells are selected (67), and potentially autoreactive B cells are eliminated (68). Our results suggest that GC formation may be necessary but not sufficient for generation or maintenance of B cell memory.

This work was supported by the Swiss National Science Foundation (grant 31-32195.91 to R.M. Zinkernagel), the Kanton of Zürich, the Deutsche Forschungsgemeinschaft (SFB243), and the Human Frontier Science Program.

Address correspondence to Rolf M. Zinkernagel, Institute of Experimental Immunology, Department of Pathology, University Hospital, Schmelzbergstrasse 12, CH-9091 Zürich, Switzerland. Phone: 41-1-255-29-89; Fax: 41-1-255-4420; E-mail: thfehr@bluewin.ch

T. Fehr's present address is Department of Internal Medicine, Stadtspital Triemli, Birmensdorferstrasse 497, 8063 Zürich, Switzerland. R.C. Rickert's present address is Department of Biology, Bonner Hall Rm. 3106, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92039-0322.

Received for publication 10 December 1997 and in revised form 6 April 1998.

Table 2. Quantitative Analysis of GCs in CD19\(^{-/-}\) and Control Mice after Immunization with VSV

| Days after immunization | Mouse strain | No. of PNA\(^{+}\) GCs* | No. of 4C11\(^{+}\) GCs* | No. of VSV-specific GCs* |
|-------------------------|--------------|-------------------------|-------------------------|-------------------------|
| 12                      | CD19\(^{+/+}\) | 32 ± 8                  | 27 ± 2                  | 15 ± 4                  |
|                         | CD19\(^{-/-}\) | 27 ± 2                  | 21 ± 5                  | 10 ± 5                  |
| 46                      | CD19\(^{+/+}\) | 40 ± 6                  | 21 ± 7                  | 10 ± 3                  |
|                         | CD19\(^{-/-}\) | 16 ± 1                  | 16 ± 1                  | 5 ± 3                   |
| 105                     | CD19\(^{+/+}\) | 59 ± 2                  | 32 ± 3                  | 7 ± 4                   |
|                         | CD19\(^{-/-}\) | 25 ± 11                 | 16 ± 7                  | 3 ± 1                   |

*Numbers ± SD indicate the amount of GCs counted per 10 visual fields at a magnification of 10.
References

1. Stashenko, P., L.M. Nadler, R. Hardy, and S.F. Schlossman. 1981. Expression of cell surface markers after human B lymphocyte activation. Proc. Natl. Acad. Sci. USA. 78:3848–3852.

2. Uckun, F.M., W.E. Evans, C.J. Forsyth, K.G. Waddick, L.T. Ahlgren, L.M. Chelstrom, A. Burkhardt, J. Bolen, and D.E. Myers. 1995. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science. 267:886–891.

3. Tedder, T.F., and C.M. Isacs. 1989. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J. Immunol. 143:712–717.

4. Zhou, L.J., D.C. Ord, A.L. Hughes, and T.F. Tedder. 1991. Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes. Conservation of the extensive cytoplasmic domain. J. Immunol. 147:1424–1432.

5. Myers, D.E., X. Jun, K.G. Waddick, C. Forsyth, L.M. Chelstrom, R.L. Gunther, N.E. Tumer, J. Bolen, and F.M. Uckun. 1995. Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells. Proc. Natl. Acad. Sci. USA. 92:9575–9579.

6. Chalupny, N.J., A. Aruffo, J.M. Esselstyn, P.Y. Chan, J. Bajorath, J. Blake, L.K. Gilliland, J.A. Ledbetter, and M.A. Tepper. 1995. Specific binding of Fyn and phosphatidylinositol 3-kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains. J. Biol. Chem. 269:32514–32521.

7. Carter, R.H., D.A. Tuveson, D.J. Park, S.G. Rhee, and D.T. Fearon. 1991. The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J. Immunol. 147:3663–3671.

8. Uckun, F.M., A.L. Burkhardt, L. Jarvis, X. Jun, B. Stealey, I. Dibirdik, D.E. Myers, L. Tuel-Ahlgren, and J.B. Bolen. 1990. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J. Biol. Chem. 265:21172–21184.

9. Bradbury, L.E., E.S. Goldmacher, and T.F. Tedder. 1993. The CD19 signal transduction complex of B lymphocytes. Deletion of the CD19 cytoplasmic domain alters signal transduction but not complex formation with TAPA-1 and Leu-13. J. Immunol. 151:2915–2927.

10. Masamoto, A.K., J. Kopicky-Burd, R.H. Carter, D.A. Tuveson, T.F. Tedder, and D.T. Fearon. 1991. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J. Exp. Med. 173:55–64.

11. Bradbury, L.E., G.S. Kansas, S. Levy, R.L. Evans, and T.F. Tedder. 1992. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 149:2841–2850.

12. Pesando, J.M., L.S. Bouchard, and B.E. McMaster. 1989. CD19 is functionally and physically associated with surface immunoglobulin. J. Exp. Med. 170:2159–2164.

13. Carter, R.H., G.M. Doody, J.B. Bolen, and D.T. Fearon. 1997. Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen receptor complex. J. Immunol. 158:3062–3069.

14. Sato, S., N. Oono, D.A. Steeber, D.S. Piesky, and T.F. Tedder. 1996. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J. Immunol. 157:4371–4378.

15. Krop, I., A.R. de Fougerolles, R.R. Hardy, M. Allison, M.S. Schlissel, and D.T. Fearon. 1996. Self-renewal of B-1 lymphocytes is dependent on CD19. Eur. J. Immunol. 26:238–242.

16. Rickert, R.C., K. Rajewsky, and J. Roses. 1995. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature. 376:352–355.

17. Engel, P., L.J. Zhou, D.C. Ord, S. Sato, B. Koller, and T.F. Tedder. 1995. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunol. 3:39–50.

18. Kansas, G.S., and T.F. Tedder. 1991. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J. Immunol. 147:4094–4102.

19. Carter, R.H., and D.T. Fearon. 1992. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science. 256:105–107.

20. Pepys, M.B. 1974. Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J. Exp. Med. 140:126–145.

21. Matsuda, T., G.P. Martinelli, and A.G. Oster. 1978. Studies on immunosuppression by cobra venom factor. II. On responses to DNP-Ficoll and DNP-Polyacrylamide. J. Immunol. 212:2048–2051.

22. O’Neill, K.M., H.D. Ochs, S.R. Heller, L.C. Cork, J.M. Morris, and J.A. Winkelstein. 1988. Role of C3 in humoral immune responses to DNP-Ficoll and DNP-Polyacrylamide. J. Immunol. 158:3062–3069.

23. Cochrane, C.G., H.J. Muller-Eberhard, and B.S. Aikin. 1970. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J. Immunol. 105:55–69.

24. Heyman, B., E.J. Wiersma, and T. Kinoshita. 1990. In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J. Exp. Med. 172:665–668.

25. Thyhronitis, G., T. Kinoshita, K. Inoue, J.E. Schweinle, G.C. Tsokos, E.S. Metchaf, F.D. Finkelman, and J.E. Balow. 1991. Modulation of mouse complement receptors 1 and 2 suppresses antibody responses in vivo. J. Immunol. 147:224–230.

26. Hebell, T.J., and T.F. Fearon. 1991. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science. 254:102–105.

27. Wessels, M.R., P. Butko, M. Ma, H.B. Warren, A.L. Lage, and M.C. Carroll. 1995. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA. 92:11490–11494.

28. Ahearn, J.M., M.B. Fischer, D. Croix, S. Goerg, M. Ma, J.
Xia, X. Zhou, R.G. Howard, T.L. Rothstein, and M.C. Carroll. 1996. Disruption of the C2r locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunology. 4:251–262.

30. Molina, H., V.M. Holers, B. Li, Y. Fung, S. M ariahaan, J. Goellner, J. Strauss-Schoenberger, R.W. Karr, and D.D. Chaplin. 1996. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. USA. 93:3357–3361.

31. Fehr, T., M.F. Bachmann, H. Bluethmann, H. Kikutani, H. Hengartner, and R.M. Zinkernagel. 1996. T-independent activation of B cells by vesicular stomatitis virus: no evidence for the need of a second signal. Cell. Immunol. 168:184–192.

32. Mills, B.J., and N.R. Cooper. 1978. Antibody-independent neutralization of vesicular stomatitis virus by human complement. I. Complement requirements. J. Immunol. 121:1549–1557.

33. Van Noesel, C.J., A.C. Lankester, and R.A. Van Lier. 1993. Dual antigen presentation by B cells. Immunol. Today. 14:8–11.

34. Dempsey, P.W., E.D. Allison, S. Akkaraju, C.C. Goodnow, and D.T. Fearon. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science. 271:348–350.

35. Fearon, D.T., and R.M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science. 272:50–53.

36. Sato, S., D.A. Steeber, and T.F. Tedder. 1995. The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc. Natl. Acad. Sci. USA. 92:11558–11562.

37. Zhou, L.J., H.M. Smith, T.J. Waldschmidt, R. Schwarting, J. Goellner, and R.M. Zinkernagel. 1994. Free recirculation of memory B cells versus antigen-dependent differentiation to antibody-forming cells. J. Immunol. 153:3386–3397.

38. Bachmann, M.F., B. Odermatt, H. Hengartner, and R.M. Zinkernagel. 1996. Induction of long-lived germinal centers associated with persisting antigen after viral infection. J. Exp. Med. 183:2259–2269.

39. Gray, D., M. Kosco, and B. Stockinger. 1991. Novel pathways of antigen presentation for the maintenance of memory. Int. Immunol. 3:141–148.

40. Fields, B.N. 1990. Virology. Lippincott-Raven Publishers.

41. Matsuura, Y., R.D. Possee, H.A. Overton, and D.H. Bishop. 1994. Expression of cytokines by recombinant vaccinia virus: kinetics and cellular sites of high level expression of proteins, including glycoproteins. J. Virol. 68:1233–1250.

42. Bachmann, M.F., T.M. Kündig, C.P. Kalberer, H. Hengartner, and R.M. Zinkernagel. 1993. Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses. J. Virol. 67:3917–3922.

43. Wagner, R.R., R.M. Snyder, and S. Yamaizaki. 1970. Proteins of vesicular stomatitis virus: genetics and cellular sites of synthesis. J. Virol. 5:548–558.

44. Scott, D.W., and R.K. Gershon. 1970. Determination of total and mercaptoethanol-resistant antibody in the same serum sample. Clin. Exp. Immunol. 6:313–316.

45. Msokophidis, D., and F. Lehmann-Grube. 1984. The immune response of the mouse to lymphocytic choriomeningitis virus. IV. Enumeration of antibody-producing cells in spleens during acute and persistent infection. J. Immunol. 133:3366–3370.

46. Bachmann, M.F., T.M. Kündig, B. Odermatt, H. Hengartner, and R.M. Zinkernagel. 1994. Free recirculation of
ruses a model for studying cytokines in virus infections in vivo. Immunol. Rev. 127:157–182.

63. Fearon, D.T. 1993. The CD19-CR2-TAP-1 complex, CD45 and signaling by the antigen receptor of B lymphocytes. Curr. Biol. 5:341–348.

64. Holder, M.J., K. Knox, and J. Gordon. 1992. Factors modifying survival pathways of germinal center B cells. Glucocorticoids and transforming growth factor-β, but not cyclosporin A or anti-CD19, block surface immunoglobulin-mediated rescue from apoptosis. Eur. J. Immunol. 22:2725–2728.

65. Herzenberg, L.A., P.A. Lalor, and A.M. Stall. 1989. Are Ly-1 B cells important in autoimmune disease? J. Autoimmun. 2(Suppl.):225–231.

66. Kelsoe, G. 1995. In situ studies of the germinal center reaction. Adv. Immunol. 60:267–288.

67. Kosco-Vilbois, M.H., H. Zentgraf, J. Gerdes, and J.Y. Bonnefoy. 1997. To “B” or not to “B” a germinal center? Immunol. Today. 18:225–230.

68. Pulendran, B., R. van Driel, and G.J. Nossal. 1997. Immunological tolerance in germinal centres. Immunol. Today. 18:27–32.

69. Liu, Y.J., J. Zhang, P.J. Lane, E.Y. Chan, and I.C. MacLennan. 1991. Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur. J. Immunol. 21:2951–2962. (See published erratum 22:615.)

70. Miller, C., and G. Kelsoe. 1995. Ig VH hypermutation is absent in the germinal centers of aged mice. J. Immunol. 155:3377–3384.

71. Han, S., K. Hathcock, B. Zheng, T.B. Kepler, R. Hodes, and G. Kelsoe. 1995. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J. Immunol. 155:556–567.

72. Mangeney, M., Y. Richard, D. Coulaud, T. Tursz, and J. Wiels. 1991. CD77: an antigen of germinal center B cells entering apoptosis. Eur. J. Immunol. 21:1131–1140.

73. Maloney, M.D., and C.A. Lingwood. 1994. CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunit: implications of molecular mimicry for B cell adhesion and enterohemorrhagic E. coli pathogenesis. J. Exp. Med. 180:191–201.